Study on the immune mechanism of treating vitiligo with fire needle

Based on the theory of cold and hot, the immune mechanism of treating vitiligo by activating il-33 /ST2 signaling pathway with fire needle was studied

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027042

Enrollment

Unknown

Registered

2019-10-29

Start date

2019-11-01

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Trial Group:fire needle

Control Group:0.1% tacrolimus ointment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 to 65 years, men and women; (2) in line with the clinical diagnostic criteria of vitiligo vulgaris; (3) skin loss area <= 10% of the surface area; (4) voluntary participation, signed informed consent.

Exclusion criteria

Exclusion criteria: (1) special parts (hair, eyes, vulva) with skin lesions; (2) the site of damage or infected; (3) scar constitution, dizzy or extremely afraid of fire needles; (4) nearly 1 month system used to treat vitiligo drugs or glucocorticoid drugs; (5) complicated with serious cardiovascular and cerebrovascular diseases, liver and kidney system diseases; (6) hemophilia, coagulation dysfunction or bleeding prone patients; (7) mental patients and pregnant women, nursing patients; (8) add patients in other clinical trials within 3 months; (9) patients with skin tumors.

Design outcomes

Secondary

Measure	Time frame
Pigment recovery area;VASI;	—

Countries

China

Contacts

Public ContactGuo Fei

Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine

407113163@qq.com+86 18599130365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026